Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Abluminal biodegradable polymer biolimus-eluting versus durable polymer everolimus-eluting stent in patients with diabetes mellitus: 5 years follow-up from the COMPARE II trial.

Paradies V, Vlachojannis GJ, Royaards KJ, Wassing J, van der Ent M, Smits PC.

Int J Cardiol. 2019 Sep 1;290:40-44. doi: 10.1016/j.ijcard.2019.04.054. Epub 2019 May 3.

2.

Coronary Angiography after Cardiac Arrest without ST-Segment Elevation.

Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen M, Rijpstra TA, Bosker HA, Blans MJ, Bleeker GB, Baak R, Vlachojannis GJ, Eikemans BJW, van der Harst P, van der Horst ICC, Voskuil M, van der Heijden JJ, Beishuizen A, Stoel M, Camaro C, van der Hoeven H, Henriques JP, Vlaar APJ, Vink MA, van den Bogaard B, Heestermans TACM, de Ruijter W, Delnoij TSR, Crijns HJGM, Jessurun GAJ, Oemrawsingh PV, Gosselink MTM, Plomp K, Magro M, Elbers PWG, van de Ven PM, Oudemans-van Straaten HM, van Royen N.

N Engl J Med. 2019 Apr 11;380(15):1397-1407. doi: 10.1056/NEJMoa1816897. Epub 2019 Mar 18.

PMID:
30883057
3.

Angiographic and Midterm Outcomes of Bioresorbable Vascular Scaffold for Coronary Bifurcation Lesions.

Paradies V, Vlachojannis GJ, Royaards KJ, Wassing J, van der Ent M, Smits PC.

Am J Cardiol. 2018 Dec 15;122(12):2035-2042. doi: 10.1016/j.amjcard.2018.09.003. Epub 2018 Sep 13.

PMID:
30360886
4.

Serial Assessment of Strut Coverage of Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months After Stent Implantation by Optical Frequency Domain Imaging: The DISCOVERY 1TO3 Study (Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Biodegradable Polymer at 1, 2, and 3 Months).

Chevalier B, Smits PC, Carrié D, Mehilli J, Van Boven AJ, Regar E, Sawaya FJ, Chamié D, Kraaijeveld AO, Hovasse T, Vlachojannis GJ.

Circ Cardiovasc Interv. 2017 Dec;10(12). pii: e004801. doi: 10.1161/CIRCINTERVENTIONS.116.004801.

5.

Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: A pooled patient-level meta-analysis of randomized trials.

De Luca G, Smits P, Hofma SH, Di Lorenzo E, Vlachojannis GJ, Van't Hof AWJ, van Boven AJ, Kedhi E, Stone GW, Suryapranata H; Drug-Eluting Stent in Primary Angioplasty (DESERT 3) cooperation.

Int J Cardiol. 2017 Oct 1;244:121-127. doi: 10.1016/j.ijcard.2017.06.022. Epub 2017 Jun 13. Review.

PMID:
28673736
6.

Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).

Vlachojannis GJ, Smits PC, Hofma SH, Togni M, Vázquez N, Valdés M, Voudris V, Slagboom T, Goy JJ, den Heijer P, van der Ent M.

JACC Cardiovasc Interv. 2017 Jun 26;10(12):1215-1221. doi: 10.1016/j.jcin.2017.02.029. Epub 2017 May 31.

7.

Potentially increased incidence of scaffold thrombosis in patients treated with Absorb BVS who terminated DAPT before 18 months.

Felix CM, Vlachojannis GJ, IJsselmuiden AJJ, Fam JM, Smits PC, Lansink WJ, Diletti R, Zijlstra F, Regar ES, Boersma E, Onuma Y, van Geuns RJM.

EuroIntervention. 2017 Jun 2;13(2):e177-e184. doi: 10.4244/EIJ-D-17-00119.

8.

Very Late Scaffold Thrombosis in Absorb BVS: Association With DAPT Termination?

Felix CM, Vlachojannis GJ, IJsselmuiden AJ, Onuma Y, van Geuns RJ.

JACC Cardiovasc Interv. 2017 Mar 27;10(6):625-626. doi: 10.1016/j.jcin.2017.01.015. No abstract available.

9.

Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions.

Fam JM, Ojeda S, Garbo R, Latib A, La Manna A, Vaquerizo B, Boukhris M, Vlachojannis GJ, van Geuns RJ, Ezhumalai B, Kawamoto H, van der Sijde J, Felix C, Pan M, Serdoz R, Boccuzzi GG, De Paolis M, Sardella G, Mancone M, Tamburino C, Smits PC, Di Mario C, Seth A, Serra A, Colombo A, Serruys P, Galassi AR, Zijlstra F, Van Mieghem NM, Diletti R.

EuroIntervention. 2017 Jun 20;13(3):355-363. doi: 10.4244/EIJ-D-16-00253.

11.

Coronary angiography after cardiac arrest: Rationale and design of the COACT trial.

Lemkes JS, Janssens GN, Straaten HM, Elbers PW, van der Hoeven NW, Tijssen JG, Otterspoor LC, Voskuil M, van der Heijden JJ, Meuwissen M, Rijpstra TA, Vlachojannis GJ, van der Vleugel RM, Nieman K, Jewbali LS, Bleeker GB, Baak R, Beishuizen B, Stoel MG, van der Harst P, Camaro C, Henriques JP, Vink MA, Gosselink MT, Bosker HA, Crijns HJ, van Royen N; COACT investigators.

Am Heart J. 2016 Oct;180:39-45. doi: 10.1016/j.ahj.2016.06.025. Epub 2016 Jul 14.

PMID:
27659881
12.

One-year results of the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study.

Giustino G, Baber U, Mastoris I, Vlachojannis GJ, Yu J, Teirstein PS, Downey WE, Batchelor WB, Casterella PJ, Nikolsky E, Wong SC, Theodoropoulos KN, Dangas GD, Mehran R.

Catheter Cardiovasc Interv. 2016 Mar;87(4):703-9. doi: 10.1002/ccd.26106. Epub 2015 Oct 20.

PMID:
26481591
13.

Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice).

Smits PC, Vlachojannis GJ, McFadden EP, Royaards KJ, Wassing J, Joesoef KS, van Mieghem C, van de Ent M.

JACC Cardiovasc Interv. 2015 Aug 17;8(9):1157-1165. doi: 10.1016/j.jcin.2015.03.028. Epub 2015 Jul 22.

14.
15.

Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis.

Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, Vlachojannis GJ, Jensen LO, Christiansen EH, Berencsi K, Valgimigli M, Orlandi C, Petrou M, Rapezzi C, Stone GW.

J Am Coll Cardiol. 2015 Jun 16;65(23):2496-507. doi: 10.1016/j.jacc.2015.04.017.

16.

Clinical and angiographic evaluation of the resolute zotarolimus-eluting coronary stent in Japanese patients – long-term outcome in the RESOLUTE Japan and RESOLUTE Japan small vessel study.

Saito S, Maehara A, Vlachojannis GJ, Parise H, Mehran R; RESOLUTE Japan Investigators.

Circ J. 2015;79(1):96-103. doi: 10.1253/circj.CJ-14-0836. Epub 2014 Nov 27.

17.

Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty.

Kini A, Yu J, Cohen MG, Mehran R, Baber U, Sartori S, Vlachojannis GJ, Kovacic JC, Pyo R, O'Neill B, Singh V, Jacobs E, Poludasu S, Moreno P, Kim MC, Krishnan P, Sharma SK, Dangas GD.

EuroIntervention. 2014 Jul;10(3):312-9. doi: 10.4244/EIJV10I3A54.

18.

Epigenetic regulation of endothelial lineage committed genes in pro-angiogenic hematopoietic and endothelial progenitor cells.

Ohtani K, Vlachojannis GJ, Koyanagi M, Boeckel JN, Urbich C, Farcas R, Bonig H, Marquez VE, Zeiher AM, Dimmeler S.

Circ Res. 2011 Nov 11;109(11):1219-29. doi: 10.1161/CIRCRESAHA.111.247304. Epub 2011 Oct 6.

PMID:
21980126
19.

Post TAVI paravalvular regurgitation: can we stop the leak?

Vlachojannis GJ, Mehran R.

Catheter Cardiovasc Interv. 2011 Sep 1;78(3):444-5. doi: 10.1002/ccd.23317. No abstract available.

PMID:
21976433
20.

Clopidogrel resistance: current aspects and future directions.

Vlachojannis GJ, Dimitropoulos G, Alexopoulos D.

Hellenic J Cardiol. 2011 May-Jun;52(3):236-45. Review. No abstract available.

21.

Intracoronary beta-radiation therapy for in-stent restenosis: long-term success rate and prediction of failure.

Vlachojannis GJ, Fichtlscherer S, Spyridopoulos I, Auch-Schwelk W, Schopohl B, Zeiher AM, Schächinger V.

J Interv Cardiol. 2010 Feb;23(1):60-5. doi: 10.1111/j.1540-8183.2009.00522.x.

PMID:
20465720
22.

Phosphorus control in peritoneal dialysis patients.

Yavuz A, Ersoy FF, Passadakis PS, Tam P, Evaggelos DM, Katopodis KP, Ozener C, Akçiçek F, Camsari T, Ateş K, Ataman R, Vlachojannis GJ, Dombros NA, Utaş C, Akpolat T, Bozfakioğlu S, Wu G, Karayaylali I, Arinsoy T, Stathakis CP, Yavuz M, Tsakiris DJ, Dimitriades AC, Yilmaz ME, Gültekin M, Süleymanlar G, Oreopoulos DG.

Kidney Int Suppl. 2008 Apr;(108):S152-8. doi: 10.1038/sj.ki.5002617.

23.

[Pacemaker quiz, 12th part].

Israel CW, Vlachojannis GJ, Trepels T, Spyridopoulos I.

Herzschrittmacherther Elektrophysiol. 2006 Jun;17(2):112-5. German. No abstract available.

PMID:
16786470
24.

Enhanced expression of group IIA secreted phospholipase A2 by elevated glucose levels in cytokine-stimulated rat mesangial cells and in kidneys of diabetic rats.

Vlachojannis GJ, Scholz-Pedretti K, Fierlbeck W, Geiger H, Pfeilschifter J, Kaszkin M.

Clin Nephrol. 2005 May;63(5):356-67.

PMID:
15909595
25.

Modulation of cytokine-induced expression of secretory phospholipase A2-type IIA by protein kinase C in rat renal mesangial cells.

Scholz K, Vlachojannis GJ, Spitzer S, Schini-Kerth V, Van Den Bosch H, Kaszkin M, Pfeilschifter J.

Biochem Pharmacol. 1999 Dec 1;58(11):1751-8.

PMID:
10571249

Supplemental Content

Loading ...
Support Center